Lead the development of innovative technology solutions in the field of data and digital to enhance the value of our drugs for the benefit of patients and physiciansLead the development of complex delivery devices, currently focusing on PPY988, Novartis’ gene therapy for the treatment of geographic atrophy from age-related macular degeneration

• Lead the development of innovative digital solutions to support patients and HCPs• Lead the development of DDO001F1, a novel digital therapy for the treatment of amblyopia

• Acquired Amblyothech, the first digital therapy for the treatment of amblyopia. Partnership with Ubisoft and McGill University for the development and commercialization of the digital therapy• Partnered with Tilak Healthcare for the co-promotion of Odysight remote monitoring app in USA, France, Spain, Belgium, Netherlands• Launched Mytherapy wet AMD app with Smartpatients in Spain and Italy• Partnered with RetinAI, leaders in the development of AI-based medical images algorithms to support clinical research and commercial SaMD• Launched the first Ophthalmology Apple research kit in the USA• Developed several medical devices/SaMD (still ongoing). Digitalization of the main ophtha endpoints (vision acuity, contrast sensitivity, 3D vision)

• Led launch preparation of Fovista, the first anti-PDGF compound for wet AMD for ex-US territories. Led commercial collaboration with Ophthothec (US rights)• Developed global medical retina strategy for the franchise in collaboration with ALCON• Led and concluded two BD&L deals in 2014 including in-licensing of Fovista for ex-US. This was the largest Novartis Pharma deal over the past 5 years• Embedded digital transformation within the franchise. The franchise has been recognized as a critical digital breakthrough and as truly innovative (5 external awards)

• Led global strategies and tactics for Lucentis in wet age-related macular degeneration (wet AMD)• Exceeded sales target several years in a raw to reach USD 2.5 bio sales in 2013. Lucentis recorded as one of Novartis' best launch• Developed and implemented strategy to manage Avastin vs Lucentis Head-to-Head trial impact• Fostered creation of innovative retina specialist added value services such as patient Iphone visual function test, clinic capacity optimization process

• Managed the assessment and optimization of countries' launch preparation in the top 12 Novartis countries. Implemented processes to ensure optimal launch preparation, leverage lessons learned from previous launches, identify gaps and make sure corrective actions were implemented when needed. • Completed 56 Launch Readiness Reviews in 2007 in therapeutic categories ranging from cardiovascular (Rasilez, Exforge), diabetes (Galvus), cox-2 to chronic obstructive pulmonary disease, Hepatitis B or severe asthma

• Led Elidel roll out in Emerging Growth markets and launch in China• Led the acceleration of the Seborrheic Dermatitis indication development. Successfully implemented shortened Ph II/III study design (adaptive seamless design approved by FDA) resulting in a launch gain of 1 year• Active participation in the FDA/EMEA labeling revision following black box warning implementation. Led collection of evidence supporting Novartis position. Main contact for countries affiliates

• Launched Elidel in US. Best dermatological launch ever. USD 94 mio in 9 months• Created an integrated Direct To Consumer (DTC) campaign (TV, print, relationship marketing, online advertising) that increased Elidel prescriptions by 29%, returning a 1.6 : 1 ROI, doubled brand awareness, and made Elidel the #1 eczema brand• Led Elidel professional promotion re-launch from message testing to creation of sales force material including visual aid and opinion leader lunch & learn CD-ROM• Led the execution of "TreatEczemaNow", a celebrity PR campaign with country music singer LeAnn Rimes and NEASE (the largest eczema patient group in USA). The national launch followed by 12 city media tours / speaker programs generated 31 mio media impressions and 125K unique website visitors

• Increased Elidel performance in my territory, ranking from #8 to 2nd in the nation. Won 2 district and 1 national sales contest for Elidel, Ritalin and Lamisil

• Redefined Cough, Cold & Allergy strategy (CHF 310 mio in 2001), including divestment of non-strategic local brands, and got buy-in from all major countries• Developed two new advertising campaigns for our key nasal decongestant brand, Otrivin, 2002 sales of CHF 102 MM, to launch its new soothing formula and its expansion into the flu segment• Identified and got approved for the development of six new cough and cold products• Negotiated with the support of BD&L several licenses in deals in the areas of allergy, nasal decongestants, and cough remedies

• Led the international management of the pediatric category (CHF 141 MM) and Internet strategy• Created a new pediatric umbrella brand (JuniorzTM) supported by a branded communication program targeted to pediatricians and parents. This included the development of a logo, packaging design, a distinctive visual identity for our pediatric activities, and six new pediatric cough and fever products. JuniorzTM has been implemented in France, Germany, Belgium, and Eastern Europe

• Achieved growth of Venoruton of +2% in a declining category. I developed a new packaging design for Venoruton and a new effervescent formulation launched in June 2000 in Germany• Led the expansion of Isostar from an isotonic drink into sports care. I managed the project from concept development through consumer research, packaging design, and product sourcing including in-licensing deals and pre-launch. Five SKUs have been launched in Spain and Switzerland in 2001• Co-ordinated the geographic roll-out of Gerber baby food into OTC and cosmeceuticals in South Africa, Poland, and Mexico

• Led the streamlining of non-profitable or non-core stock keeping units (SKUs). Reduction of 50 SKUs (5% of total portfolio) in 2 years• Created and implemented worldwide, a simple process for approval of new product launches. 180 SKUs were approved by the end of 1998

• Ensured the provision of the timely and comprehensive market, consumer, and competitor information